Companies › Processa Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Eniluracil (PCS6422) Dihydropyrimidine dehydrogenase inhibitor | DPYD | Phase 2 | Breast Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06568692 | Eniluracil (PCS6422) | Phase 2 | Breast Cancer | Oncology | Jul 2026 |
Cash of $0m on 2026-06-30; operating cash outflow about $11m a year; runway about 0 months at that burn, to Jul 2026
Press releases filed as 8-K in the last year:
–
Moleculin Biotech Dogwood Therapeutics Atossa Therapeutics Curis CNS Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.